Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine

Journal of Acquired Immune Deficiency Syndromes

Volumn 58, Issue 1, 2011, Pages 18-22

  Tambuyzer, Lotke ^a   Nijs, Steven ^a   Daems, Bjorn ^a   Picchio, Gaston ^b   Vingerhoets, Johan ^a  

^a TIBOTEC BVBA   (Belgium)

^b Tibotec Inc   (United States)

Author keywords

E138 mutation; Etravirine; Genotype; Phenotype; Resistance; Reverse transcriptase

Indexed keywords

ETRAVIRINE; RNA DIRECTED DNA POLYMERASE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PYRIDAZINE DERIVATIVE; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1;

ARTICLE; CLINICAL ARTICLE; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRAL GENETICS; VIROLOGY; VIRUS MUTANT; VIRUS MUTATION; AMINO ACID SEQUENCE; ANTIVIRAL RESISTANCE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MUTATION;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GENE EXPRESSION REGULATION, VIRAL; GENOTYPE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MUTATION; PHENOTYPE; PYRIDAZINES;

EID: 80055110312     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182237f74     Document Type: Article

References (21)

1. Vingerhoets J, Tambuyzer L, Azijn H, et al. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the DUET studies. AIDS. 2010;24:503-514.
2. Tambuyzer L, Vingerhoets J, Azijn H, et al. Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies. AIDS Res Hum Retroviruses. 2010;26:1197-1205.
3. Kohlstaedt LA, Wang J, Friedman JM, et al. Crystal structure at 3.5 A° resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science. 1992;256:1783-1790.
4. de Bethune MP. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). Antiviral Res. 2010;85:75-90.
5. Hertogs K, de Béthune MP, Miller V, et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother. 1998;42:269-276. (Pubitemid 28114430)
6. Pauwels R, Hertogs K, Kemp S, et al. Comprehensive HIV drug resistance monitoring using rapid, high-throughput phenotypic and genotypic assays with correlative data analysis. Presented at the 2nd International Workshop HIV Drug Resistance; 1998; Lake Maggiore, Italy. Abstract 51.
7. Azijn H, Tirry I, Vingerhoets J, et al. TMC278, a next-generation NNRTI, active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother. 2010;54:718-727.
8. Katlama C, Clotet B, Mills A, et al. Efficacy and safety of etravirine at Week 96 in treatment-experienced HIV-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther. 2010;15:1045-1052.
9. Tambuyzer L, Azijn H, Rimsky LT, et al. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors. Antivir Ther. 2009;14:103-109.
10. Pelemans H, Aertsen A, Van Laethem K, et al. Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138. Virology. 2001;280:97-106. (Pubitemid 34162519)
11. Jonckheere H, Taymans JM, Balzarini J, et al. Resistance of HIV-1 reverse transcriptase against [2', 5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"- (4"-amino-1", 2"-oxathiole-2", 2"-dioxide)] (TSAO) derivatives is determined by the mutation Glu138->Lys on the p51 subunit. J Biol Chem. 1994;269:25255-25258.
12. Balzarini J, Karlsson A, Vandamme A-M, et al. Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2', 5'-bis-O-(tertbutyldimethylsilyl)-3'-spiro-5"-(4"-amino-1", 2"-oxathiole-2", 2"-dioxide)]-f8-D-pentofuranosyl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors. Proc Natl Acad Sci U S A. 1993;90:6952-6956. (Pubitemid 23222366)
13. Balzarini J, Karlsson A, Pérez-Pérez MJ, et al. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. J Virol. 1993;67:5353-5359. (Pubitemid 23241368)
14. * C1811) RT HIV-1 mutants. Proc Natl Acad Sci U S A. 1994;91:6599-6603.
15. Balzarini J. Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy. Biochem Pharmacol. 1999;58:1-27.
16. Asahchop E, Oliveira M, Wainberg M, et al. Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HiV-1 subtypes. Antimicrob Agents Chemother. 2011;55:600-607
17. Jakubik JJ, Chapron C, Hubbard L, et al. In vitro cross-resistance profile for a next-generation NNRTI: IDX899. Antiviral Ther. 2008;13(suppl 3):A28.
18. Rimsky L, Eron J, Clotet B, et al. Characterization of the resistance profile of TMC278:48-week analysis of the Phase III studies ECHO and THRIVE. Presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2010; Boston, MA. Abstract H-1810.
19. Kagan RM, Sista P, Pattery T, et al. Additional HIV-1 mutation patterns associated with reduced phenotypic susceptibility to etravirine in clinical samples. AIDS. 2009;23:1602-1605.
20. Winters B, Villacian J, Van Craenenbroeck E, et al. Development of virco (r) type HIV-1 resistance analysis, including clinical cutoffs for TMC125 (etravirine, ETR), a new NNRTI. Presented at the 15th Conference on Retroviruses and Opportunistic Infections; 2008; Boston, MA. Abstract 873.
21. Haddad M, Stawiski E, Benhamida J, et al. Improved genotypic algorithm for predicting etravirine susceptibility: comprehensive list of mutations identified through correlation with matched phenotype. Presented at the 17th Conference on Retroviruses and Opportunistic Infections; 2010; San Francisco, CA. Abstract 574.